Evolution in the sensitivity of quantitative HIV-1 viral load tests

Journal of Clinical Virology

Volumn 52, Issue SUPPL. 1, 2011, Pages

  Cobb, Bryan R ^a   Vaks, Jeffrey E ^a   Do, Tri ^a   Vilchez, Regis A ^a  

^a ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

HIV viral load; HIV 1; Lower limit of detection; Lower limit of quantification; Real time PCR

Indexed keywords

VIRUS RNA;

ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD;

GUIDELINES AS TOPIC; HIV INFECTIONS; HIV-1; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 83155181438     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.09.015     Document Type: Article

References (48)

1. Sizmann D., Glaubitz J., Simon C.O., Goedel S., Buergisser P., Drogan D., et al. Improved HIV-1 RNA quantitation by COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 using a novel dual-target approach. J Clin Virol 2010, 49:41-46.
2. Espy M.J., Uhl J.R., Sloan L.M., Buckwalter S.P., Jones M.F., Vetter E.A., et al. Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol Rev 2006, 19:165-256.
3. Damond F., Avettand-Fenoel V., Collin G., Roquebert B., Plantier J.C., Ganon A., et al. Evaluation of an upgraded version of the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 test for HIV-1 load quantification. J Clin Microbiol 2010, 48:1413-1416.
4. Scott L., Carmona S., Stevens W. Performance of the new Roche COBAS AmpliPrep-COBAS TaqMan version 2.0 human immunodeficiency virus type 1 test. J Clin Microbiol 2009, 47:3400-3402.
5. De Bel A., Marissens D., Debaisieux L., Liesnard C., Van den Wijngaert S., et al. Correction of underquantification of human immunodeficiency virus type 1 load with the second version of the Roche COBAS AmpliPrep/COBAS TaqMan assay. J Clin Microbiol 2010, 48:1337-1342.
6. Wirden M., Tubiana R., Fourati S., Thevenin M., Simon A., Canestri A., et al. Upgraded COBAS Ampliprep-COBAS TaqMan Version 2.0 HIV-1 RNA quantification assay versus first version: correction of underestimations. J Clin Microbiol 2011, 49:2700-2702.
7. Hammer S.M., Eron J.J., Reiss P., Schooley R.T., Thompson M.A., Walmsley S., et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300:555-570.
8. Holmes H., Davis C., Heath A., Hewlett I., Lelie N. An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques. J Virol Methods 2001, 92:141-150.
9. Elbeik T., Alvord W.G., Trichavaroj R., de Souza M., Dewar R., Brown A., et al. Comparative analysis of HIV-1 viral load tests on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5. J Acquir Immune Defic Syndr 2002, 29:330-339.
10. Taylor N., Schmid I., Egle A., Greil R., Patsch W., Oberkofler H. Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals. Antivir Ther 2009, 14:1189-1193.
11. Pas S., Rossen J.W., Schoener D., Thamke D., Pettersson A., Babiel R., et al. Performance evaluation of the new Roche COBAS AmpliPrep COBAS TaqMan HIV-1 test version 2.0 for the quantification of HIV-1 RNA. J Clin Microbiol 2010, 48:1195-1200.
12. Montaner J.S., Richman D.D., Hammer SM International AIDS Society-USA Antiretroviral Guidelines Panel Poor agreement between 2 tests for measuring low levels of HIV-1 viral load. Clin Infect Dis 2009, 48:1283-1284.
13. Lima V., Harrigan R., Montaner J.S. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 2009, 51:3-6.
14. Smit E., Bhattacharya S., Osman H., Taylor S. Increased frequency of HIV-1 viral load blip rate observed after switching from Roche COBAS Amplicor to COBAS TaqMan assay. J Acquir Immune Defic Syndr 2009, 51:364-365.
15. Szabo S., Moffett L.E., Cantwell-McNelis K., James C.W., Joseph A. Low-level viremia associated with the use of TaqMan assay. J Int Assoc Physicians AIDS Care (Chic) 2010, 9:203-205.
16. de Boer M.G., Wessels E., Claas E.C., Kroon F.P. Potential influence of more-sensitive HIV-1 load detection by the new Roche COBAS AmpliPrep/COBAS TaqMan version 2.0 assay on clinical management of HIV-positive pregnant women. J Clin Microbiol 2010, 48:4301-4302.
17. Glaubitz J., Sizmann D., Simon C.O., Hoffmann K.S., Drogan D., Hesse M., et al. Accuracy to 2nd International HIV-1 RNA WHO Standard: Assessment of three generations of quantitative HIV-1 RNA nucleic acid amplification tests. J Clin Virol 2011, 50:119-124.
18. Yan C.S., Hanafi I., Kelleher A.D., Carr A.D., Amin J., McNally L.P., et al. Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification. J Clin Virol 2010, 49:249-253.
19. Bourlet T., Signori-Schmuck A., Roche L., Icard V., Saoudin H., Trabaud M.A., et al. HIV-1 load comparison using four commercial real-time assays. J Clin Microbiol 2011, 49:292-297.
20. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents 2011, January 10. p. 1-166. Available at: http://www.aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf [accessed 22.06.11].
21. Sebire K., McGavin K., Land S., Middleton T., Birch C. Stability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCR-based assay. J Clin Microbiol 1998, 36:493-498.
22. Evaluation of linearity of quantitative measurement procedures: a statistical approach; approved guideline. CLSI Document EP6-A [ISBN 1-56238-498-8]. 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA; 2004.
23. Sabino E.C., Gaburo N., Leite J.P., Viecili M., Rosenfeld L.G. Platelets may affect detection and quantitation of HIV RNA in plasma samples with low viral loads. J Acquir Immune Defic Syndr 2004, 37:1432-1433.
24. Stosor V., Palella F.J., Berzins B., Till M., Leake A., Chmiel J.S., et al. Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin Infect Dis 2005, 41:1671-1674.
25. Salimnia H., Moore E.C., Crane L.R., Macarthur R.D., Fairfax M.R. Discordance between viral loads determined by Roche COBAS AMPLICOR human immunodeficiency virus type 1 monitor (version 1.5) standard and ultrasensitive tests caused by freezing patient plasma in centrifuged Becton-Dickinson Vacutainer brand plasma preparation tubes. J Clin Microbiol 2005, 43:4635-4639.
26. García-Bujalance S., Ladrón de Guevara C., González-García J., Arribas J.R., Zamora F., Gutiérrez A. Elevation of viral load by PCR and use of plasma preparation tubes for quantification of human immunodeficiency virus type 1. J Microbiol Methods 2007, 69:384-386.
27. Griffith B.P., Mayo D.R. Increased levels of HIV RNA detected in samples with viral loads close to the detection limit collected in plasma preparation tubes (PPT). J Clin Virol 2006, 35:197-200.
28. Rebeiro P., Kheshti A., Bebawy S., Stinnette S.E., Erdem H., Tang Y.W., et al. Increased detectability of plasma HIV-1 RNA after Introduction of a new assay and altered specimen-processing procedures. Clin Infect Dis 2008, 47:1354-1357.
29. Kran A.M., Jonassen T.O., Sannes M., Jakobsen K., Lind A., Maeland A., et al. Overestimation of human immunodeficiency virus type 1 load caused by the presence of cells in plasma from plasma preparation tubes. J Clin Microbiol 2009, 47:2170-2174.
30. Abbott Realtime HIV-1 [package insert], Des Plaines 2007, Abbott Molecular Inc., IL.
31. Protocols for determination of limits of detection and limits of quantitation; Approved Guideline. CLSI document EP17-A (ISBN 1-56238-551-8). 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA; 2004.
32. Evaluation of precision performance of quantitative measurement methods; approved guideline-second edition. CLSI document EP5-A2 [ISBN 1-56238-542-9]. 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA; 2004.
33. COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, version 2.0 [package insert] 2010, Roche Molecular Systems, Inc., Branchburg, NJ.
34. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents 1999, Department of Health and Human Services (DHHS), Baltimore, MD.
35. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents 2011, Department of Health and Human Services (DHHS), Baltimore, MD.
36. Maldarelli F., Palmer S., King M.S., Wiegand A., Polis M.A., Mican J., et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007, 4:e46.
37. Pockros P.J. New drugs for hepatitis C virus. Expert Rev Gastroenterol Hepatol 2007, 1:145-154.
38. Ribaudo H., Lennox J., Currier J., Kuritzkes D., Gulick R., Haubrich R., et al. Virologic failure endpoint definition in clinical trials: is using HIV-1 RNA threshold <200copies/mL better than <50copies/mL? An analysis of ACTG studies. Abstract #580 presented at 16th conference on retroviruses and opportunistic infections 2009.
39. Chun T.W., Carruth L., Finzi D., Shen X., DiGuiseppe J.A., Taylor H., et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188.
40. Moir S., Chun T.W., Fauci A.S. Pathogenic mechanisms of HIV disease. Annu Rev Pathol 2011, 6:223-248.
41. Lehrman G., Hogue I.B., Palmer S., Jennings C., Spina C.A., Wiegand A. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005, 366:549-555.
42. Winters M.A., Tan L.B., Katzenstein D.A., Merigan T.C. Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol 1993, 31:2960-2966.
43. Palmer S., Maldarelli F., Wiegand A., Bernstein B., Hanna G.J., Brun S.C., et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008, 105:3879-3884.
44. Havlir D.V., Bassett R., Levitan D., Gilbert P., Tebas P., Collier A.C., et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001, 286:171-179.
45. Deeks S.G. Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure. JAMA 2001, 286:224-226.
46. Nettles R.E., Kieffer T.L., Kwon P., Monie D., Han Y., Parsons T., et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005, 293:817-829.
47. Sklar P.A., Ward D.J., Baker R.K., Wood K.C., Gafoor Z., Alzola C.R., et al. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 2002, 16:2035-2041.
48. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 78:1295-1300.